11
total announcements
NATHBIOGEN.BO · 15 min delayed
Key Stats · Yahoo Finance · as of 04 Nov 2026
Market Cap
₹267 Cr
P/E (TTM)
7.2
EPS (TTM)
₹18.43
52W Low
₹126.75
52W High
₹207.00
Dividend Yield
1.52%
Beta
0.84
Price / Book
0.4
Debt / Equity
20.4
Revenue (TTM)
₹490 Cr
Gross Margin
53.76%
Operating Margin
10.40%
Nath Bio-Genes (India) Ltd
Nath Bio-Genes (India) Ltd has submitted a compliance certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018, confirming the dematerialization of securities up to 30th September 2026.
Nath Bio-Genes (India) Ltd
Nath Bio-Genes (India) Ltd has announced the closure of its trading window from October 1, 2026, until 48 hours after the declaration of unaudited financial results for the quarter and half-year ending September 30, 2026.
Nath Bio-Genes (India) Ltd
Nath Bio-Genes (India) Ltd held its 33rd Annual General Meeting on September 24, 2026, via video conferencing. The meeting approved resolutions including the audited standalone and consolidated balance sheet, final dividend, director appointments, and remuneration revision. The e-voting results are being disseminated to stock exchanges and uploaded on the company's website.
Nath Bio-Genes (India) Ltd
Nath Bio-Genes (India) Ltd has announced the record date for its 33rd Annual General Meeting and dividend eligibility, scheduled for September 11, 2026.
Nath Bio-Genes (India) Ltd
Nath Bio-Genes (India) Ltd has announced the record date for its 33rd Annual General Meeting, scheduled to be held on September 24, 2026, through video conferencing. The cut-off date for determining member eligibility to vote is September 11, 2026.
Nath Bio-Genes (India) Ltd
Nath Bio-Genes (India) Ltd has submitted its Notice of Annual General Meeting and Annual Report for the financial year 2025-26, including the adoption of financial statements, declaration of dividend, and re-appointment of a director.
Nath Bio-Genes (India) Ltd
Nath Bio-Genes (India) Ltd has announced its 33rd Annual General Meeting (AGM) and Annual Report for the financial year 2025-26. The AGM will be held on September 24, 2026, through video conferencing. The company will consider adopting the audited financial statements, declaring a final dividend of ₹ 2 per equity share, and re-appointing a director retiring by rotation.
Nath Bio-Genes (India) Ltd
Nath Bio-Genes (India) Ltd has received a communication from SEBI informing the company that a forensic audit has been initiated by SEBI to examine the company's books of account and records for the financial years 2020-21 to 2025-26.
Nath Bio-Genes (India) Ltd
Nath Bio-Genes (India) Ltd has announced its unaudited financial results for Q1FY27, showing a 15% increase in revenue to ₹3,228 Mn, a 13% increase in gross profit to ₹1,629 Mn, and a 17% increase in EBITDA to ₹351 Mn. The company has also reported a 12% increase in PAT to ₹327 Mn and a 12% increase in EPS to ₹17.18.
Nath Bio-Genes (India) Ltd
Nath Bio-Genes (India) Ltd has announced its unaudited financial results for the quarter ended 30th June 2026, with a net profit of Rs. 3265.68 lakhs and a revenue from operations of Rs. 32284.28 lakhs.
Nath Bio-Genes (India) Ltd
Nath Bio-Genes (India) Ltd has submitted a compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, confirming that securities received for dematerialization up to 30th June 2026 have been confirmed and listed on the stock exchange.